Provided by Tiger Fintech (Singapore) Pte. Ltd.

Soleno Therapeutics

77.34
-0.2600-0.34%
Volume:10.30K
Turnover:799.74K
Market Cap:3.90B
PE:-16.65
High:78.35
Open:77.96
Low:77.01
Close:77.60
Loading ...

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA), Soleno Therapeutics (SLNO) and Adaptive Biotechnologies (ADPT)

TIPRANKS
·
12 Jun

Soleno Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
07 Jun

Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation

MT Newswires Live
·
23 May

Soleno Therapeutics seeking regulatory approval in treatment of PWS

TIPRANKS
·
23 May

Soleno Therapeutics Announces Submission and Ema Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients With Prader-Willi Syndrome

THOMSON REUTERS
·
23 May

Soleno Therapeutics presents Vykat XR data at Pediatric Endocrine Society

TIPRANKS
·
21 May

Piper Sandler Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

TIPRANKS
·
20 May

Soleno Therapeutics Announces Presentations Featuring Vykat(Tm) Xr in Prader-Willi Syndrome at Pes 2025

THOMSON REUTERS
·
15 May

Stock Track | Soleno Therapeutics Soars 7.17% as Multiple Analysts Boost Price Targets

Stock Track
·
08 May

Soleno Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
08 May

Stifel Nicolaus Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

TIPRANKS
·
08 May

Stock Track | Soleno Therapeutics Soars 7.15% Pre-market on Guggenheim's Bullish Target Price Hike

Stock Track
·
08 May

Soleno Therapeutics Inc : Guggenheim Raises Target Price to $97 From $81

THOMSON REUTERS
·
08 May

Earnings Flash (SLNO) Soleno Therapeutics Q1 Loss $0.95 Vs. FactSet Est. Loss $0.97

MT Newswires Live
·
08 May

Soleno Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Soleno Therapeutics Q1 GAAP EPS $(0.95) Misses $(0.81) Estimate

Benzinga
·
08 May

Soleno Therapeutics Q1 Operating Expenses USD 45.743 Million

THOMSON REUTERS
·
08 May

Soleno Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
24 Apr

Soleno Therapeutics price target raised to $145 from $93 at Piper Sandler

TIPRANKS
·
24 Apr

Piper Sandler Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)

TIPRANKS
·
24 Apr